ResearcherHospital Universitario HM SanchinarroNo recent work listed
Rafael Álvarez
Matched on ORCID iD 0000-0002-1186-8038; OpenAlex author ID A5103156291. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper
Papers 6
- A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation … Co-author DOI 10.1007/s12094-020-02287-w↗
- Management and supportive treatment of frail patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.jgo.2018.06.005↗
- Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12094-017-1680-8↗
- Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejso.2016.01.006↗
- Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. Co-author DOI 10.1038/bjc.2014.129↗
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.415↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Manuel M. Hidalgo · 5 shared papers, 2013–2019 · strength 0.30
- Paper Management and supportive treatment of frail patients with metastatic pancreatic cancer. DOI 10.1016/j.jgo.2018.06.005↗
- Paper Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. DOI 10.1007/s12094-017-1680-8↗
- Paper Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenoca… DOI 10.1016/j.ejso.2016.01.006↗
- Carlos Plaza · 4 shared papers, 2013–2020 · strength 0.20
- Paper A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a… DOI 10.1007/s12094-020-02287-w↗
- Paper Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenoca… DOI 10.1016/j.ejso.2016.01.006↗
- Paper Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. DOI 10.1038/bjc.2014.129↗
- Yolanda Quijano · 4 shared papers, 2013–2020 · strength 0.20
- Paper A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a… DOI 10.1007/s12094-020-02287-w↗
- Paper Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenoca… DOI 10.1016/j.ejso.2016.01.006↗
- Paper Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. DOI 10.1038/bjc.2014.129↗
- Emilio Vicente · 4 shared papers, 2013–2020 · strength 0.20
- Paper A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a… DOI 10.1007/s12094-020-02287-w↗
- Paper Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenoca… DOI 10.1016/j.ejso.2016.01.006↗
- Paper Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. DOI 10.1038/bjc.2014.129↗
- Antonio Cubillo · 3 shared papers, 2013–2020 · strength 0.15
- Paper A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a… DOI 10.1007/s12094-020-02287-w↗
- Paper Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. DOI 10.1038/bjc.2014.129↗
- Paper Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. DOI 10.1038/bjc.2013.415↗
- Adelaida Garcia-Velasco · 1 shared paper, 2019 · strength 0.10
- Berta Laquente · 1 shared paper, 2019 · strength 0.10
- Alfredo Carrato · 1 shared paper, 2019 · strength 0.10
- Teresa Mercade Macarulla · 1 shared paper, 2019 · strength 0.10
- Carmen Rubio · 1 shared paper, 2020 · strength 0.09
- Xin Chen-Zhao · 1 shared paper, 2020 · strength 0.09
- Jesús Rodríguez-Pascual · 2 shared papers, 2013–2014 · strength 0.06
- Mariano Barbacid · 2 shared papers, 2013–2014 · strength 0.06
- Carmen E. Guerra · 2 shared papers, 2013–2014 · strength 0.06
- Riccardo R.C. Caruso · 1 shared paper, 2016 · strength 0.05
- Benedetto Ielpo · 1 shared paper, 2016 · strength 0.05
- Hipólito J. Durán · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.